May 2023 $22 M No. 4 $10 to $50 million 107
Elucida Oncology, Inc.: Raise no. 4, May 2023 × Investors in this round 107 investors had bought by the notice of Aug 3, 2023: 107 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $22 M of $22 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $2,228,460
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Geno Germano · Executive Officer, Director Robert Essner · Executive Officer, Director David Zacardelli · Director Gary Sender · Director Natalie MacDonald · Director Robert Ruffolo · Director Tim Boris · Director Ulrich Wiesner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · New York, New York Sold in all US states Remarks in the notice On fees: “In addition, the Company issued the Placement Agent Warrants to purchase 526,316 shares of Common Stock of Elucida in connection with the offering.”Signed by Geno Germano, Ceo. Newest notice filed Aug 3, 2023 (1 amendment). Read the notice at the SEC .
debt, options SEC Oct 2020 $35 M No. 3 $10 to $50 million 328
Elucida Oncology, Inc.: Raise no. 3, Oct 2020 × Investors in this round 328 investors had bought by the notice of Jan 12, 2021: 328 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $35 M of $35 M offered
Smallest investment taken $12,500
What was sold equity, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $3,500,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eliel Bayever · Executive Officer Geno Germano · Executive Officer, Director Gregory Adams · Executive Officer Kai Ma · Executive Officer Robert Essner · Executive Officer, Director Michael Smith · Director Robert Ruffolo · Director Teresa Ressel · Director Tim Boris · Director Ulrich Wiesner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 12078) · New York, New York Sold in all US states Remarks in the notice On fees: “In addition, the Company issued the placement agent Warrants to purchase 4,605,246 shares of common stock of Elucida in connection with the offering.”Signed by Geno Germano, Ceo. Newest notice filed Jan 12, 2021 (3 amendments). Read the notice at the SEC .
equity SEC May 2020 $9 M No. 2 $2 to $10 million 126
Elucida Oncology, Inc.: Raise no. 2, May 2020 × Investors in this round 126 investors had bought by the notice of Jun 4, 2020: 126 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $30 M offered; $21 M still to sell
Smallest investment taken $11,400
What was sold equity, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $774,072
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Geno Germano · Executive Officer, Director Robert Essner · Executive Officer, Director Michael Smith · Director Robert Ruffolo · Director Teresa Ressel · Director Tim Boris · Director Ulrich Wiesner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 12078) · New York, New York Sold in all US states Remarks in the notice On fees: “In addition, the Company issued the placement agent Warrants to purchase 1,150,096 shares of common stock of Elucida in connection with the offering.”Signed by Geno Germano, Ceo. Newest notice filed Jun 4, 2020 (1 amendment). Read the notice at the SEC .
equity SEC Aug 2017 $29 M No. 1 $10 to $50 million 175
Elucida Oncology, Inc.: Raise no. 1, Aug 2017 × Investors in this round 175 investors had bought by the notice of Feb 7, 2019: 175 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $29 M of $30 M offered; $1 M still to sell
Smallest investment taken $25,000
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $2,875,960
Finders' fees none
Paid to its own people $400,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Geno Germano · Executive Officer, Director · Chief Executive Officer Isaac Blech · Director Michael T. Smith · Director Robert A. Essner · Director Robert A. Ruffolo · Director Teresa M. Ressel · Director Tim Boris · Director Ulrich T. Wiesner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 12078) · New York, New York Sold in all US states Remarks in the notice On the use of proceeds: “Upon a closing of $15 million in the aggregate, Mr. Edward Rosen, the Company's former CEO, is entitled to the receive up to $400,000 relating to various consulting fees and the reimbursement of expenses pursuant to the terms of his employment agreement.”Signed by Geno Germano, Chief Executive Officer. Newest notice filed Feb 7, 2019 (2 amendments). Read the notice at the SEC .
equity, options SEC